TiGenix Presents Positive Results of Potential Crohn’s Therapy, Announces Phase 3 Study

TiGenix Presents Positive Results of Potential Crohn’s Therapy, Announces Phase 3 Study
TiGenix will present positive results of Cx601 to treat complex perianal fistulas in Crohn’s disease patients at the upcoming World Congress of Gastroenterology ACG 2017 meeting in Orlando, Florida. The company will discuss results from its 52-week ADMIRE-CD Phase 3 trial (NCT01541579) and present the upcoming ADMIRE-CD-II (NCT03279081) — a global Phase 3 clinical trial designed to support

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *